| Filed On | Filing |
|---|---|
| 04 Apr 2023 |
8-K/A: Results of Operations and Financial Condition
Report of Independent Registered Public Accounting Firm (KPMG LLP, Philadelphia, PA, Auditor Firm ID: 185) |
| 11 Aug 2022 |
8-K/A: Costs Associated with Exit or Disposal Activities
This Current Report on Form 8-K/A amends and supplements the Current Report on Form 8-K filed on July 20, 2022 (the “Original Form 8-K”) by Sesen Bio, Inc. (the “Company”) announcing that, on July 15, 2022, the Company approved a restruc... |
| 11 May 2020 |
8-K/A: Other Events
Sesen Bio Reports Positive Interactions with EMA on Regulatory Pathway for Vicinium® No additional clinical trials were requested by the CHMP for submission of Vicinium marketing authorization application Anticipated submission of market... |
| 26 Feb 2020 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Wendy L. Dixon, Ph.D. resigned from the Board as a Class II director effective 6:00 am EST on February 24, 2020. Dr. Dixon’s retirement from the Board was not due to any disagreement with the Company on any matter relating to the Company... |
| 08 Aug 2019 |
8-K/A: Results of Operations and Financial Condition; Other Events
On August 7, 2019, Sesen Bio, Inc. (the “Company”) disclosed in an updated corporate presentation that it had cash and cash equivalents of $64.9 million as of June 30, 2019. |
| 18 Oct 2017 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On October 13, 2017, the Company announced that the Board appointed Richard F. Fitzgerald, age 54, as the Company’s Interim Chief Financial Officer, effective October 20, 2017. In connection with Mr. Fitzgerald’s appointment, the Company... |
| 06 Dec 2016 |
8-K/A: Completion of Acquisition or Disposition of Assets
On September 20, 2016, Eleven Biotherapeutics, Inc. (the Company or Eleven) entered into a Share Purchase Agreement with Viventia Bio Inc., a corporation incorporated under the laws of the Province of Ontario, Canada (Viventia), the shar... |
Loading...